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Dementia is a common neuropsychological disorder with an increasing incidence. The most 
prevalent of the different types of dementia is Alzheimer’s disease. The underlying 
pathophysiological features of the cognitive decline are neurodegenerative processes, a 
cerebrovascular dysfunction and immunological alterations. The therapeutic approaches are 
still limited, although intensive research is being conducted with the aim of finding 
neuroprotective strategies. The widely accepted cholinesterase inhibitors and glutamate 
antagonists did not meet the expectations that they would prevent disease progression, and the 
research is therefore currently focusing on novel targets. Nonsteroidal anti-inflammatory 
drugs, secretase inhibitors and statins are promising drug candidates for the prevention and 
management of different forms of dementia. The kynurenine pathway has been associated 
with various neurodegenerative disorders and cerebrovascular diseases, it is closely related to 
neuroinflammatory processes too, and it has been implicated in the pathomechanisms of 
certain kinds of dementia. Targeting the kynurenine system may be of therapeutic value in the 
future.  
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1. Introduction 
Dementia is an acquired cognitive decline, beyond what might be attributed to normal aging.  
It is a general term referring to a clinical syndrome of multiple cognitive deficits with several 
different underlying pathologies. The classification of the various dementia types may be 
based on genetic, pathological or clinical features. The prevalence and incidence data reveal 
an increasing tendency in parallel with the aging of the population. The overall prevalence of 
dementia is around 6-8% [De Ronchi et al., 2005, De Deyn et al., 2011, Mejia-Arango et al., 
2011], with the most prevalent type being Alzheimer’s disease (AD) [Nestor et al., 2004]. 
The main pathogenic mechanisms involved in the development of dementia are 
neurodegeneration and a cerebrovascular dysfunction, which have been recognized to be 
closely associated [Iadecola et al., 2003, Iadecola, 2010, Honjo et al., 2012, Liu et al., 2012]. 
There are a number of common features in the pathomechanisms of neurodegenerative 
processes, including mitochondrial disturbances [Karbowski et al., 2012, Szalardy et al., 
2012], neuroinflammation [Glass et al., 2010], glutamate excitotoxicity [Lau et al., 2010] and 
oxidative stress [Gandhi et al., 2012]. Excitotoxic damage to neuronal cells is caused by the 
overactivation of glutamate receptors, inhibition of which could therefore be a promising 
neuroprotective strategy. A valuable endogenous neuroprotective molecule is kynurenic acid 
(KYNA), a tryptophan (TRP) metabolite produced in the kynurenine pathway (KP), which 
exerts broad-spectrum endogenous excitatory amino acid receptor antagonistic properties 
[Perkins et al., 1982, Birch et al., 1988, Kessler et al., 1989].  
There is currently no definite cure for dementia syndromes, although intensive research is 
under way 2with a view to the development of novel therapeutic interventions that may be 
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able to prevent or slow down the progression of the disease, thereby improving the quality of 
life of the patients. The KP offers a valuable target for neuroprotective therapies. 
2. Dementia aetiology and diagnosis  
The diagnosis of the dementia syndrome is usually based on the DSM-IV criteria [American 
Psychiatric Association. et al., 2000, Feldman et al., 2008].  
The diagnostic criteria for dementia are the following: 
! An acquired memory decline and a severe impairment in one or more cognitive 
domains, including gnosis, executive function, praxis and language  
! Cognitive impairments that interfere with work or social activities 
A number of brief cognitive tests are available for the assessment of the overall cognitive 
performance, the most widely used being the highly sensitive and specific Mini-Mental State 
Examination (MMSE) [Folstein et al., 1975], and the clock-drawing test [Shulman, 2000]. 
Other tests include the Montreal Cognitive Assessment [Nasreddine et al., 2005], DemTect 
[Kalbe et al., 2004], the 7-Minute Screen [Solomon et al., 1998] and the Behavioural 
Neurology Assessment short form [Darvesh et al., 2005], which are more accurate in cases of 
mild dementia. After recognition of a cognitive impairment, detailed clinical evaluation, 
specific laboratory tests and structural neuroimaging may help to identify the aetiology 
[Feldman et al., 2008, Gauthier et al., 2012]. The most common types of dementia are AD 
and vascular dementia, but there are multiple other pathologies which may lead to a cognitive 
decline (Table 1). 
Table 1. The most common dementia types 
! Alzheimer’s disease 
! Vascular dementia and vascular cognitive impairment 
! Dementia with extrapyramidal syndromes 
o Huntington’s disease 
o Parkinson’s disease 
o Lewy bodies dementia 
! Frontotemporal dementias 
! Other dementia types  
o AIDS-dementia complex  
o Normal pressure hydrocephalus 
o Prion diseases 
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The hallmark neuropathological features of the most common dementia form, AD, are 
amyloid-ß protein deposition in senile plaques and cerebral blood vessels, and tau deposition 
in the neurons forming neurofibrillary tangles. The other main form, vascular dementia, is 
defined as the common presence of a cognitive decline and a cerebrovascular disorder. Recent 
findings provided evidence that a cerebrovascular dysfunction and neurodegenerative 
processes are strongly associated during the development of dementia [Iadecola et al., 2003]. 
Vascular risk factors may accelerate amyloid ß production and deposition, thereby 
contributing to disease progression in AD. Likevise, amyloid deposition causes cerebral 
amyloid angiopathy, which results in a disturbed cerebral perfusion [Thal et al., 2008, Honjo 
et al., 2012]. Neuroimaging studies have demonstrated that a reduced cerebral blood flow can 
be associated with early stages of AD, and cerebral hypoperfusion may precede the clinical 
symptoms of dementia and contribute to the development of AD [Rombouts et al., 2005, 
Ruitenberg et al., 2005]. A cerebrovascular dysfunction may contribute markedly to the 
development of neurodegenerative processes. Other vascular dementia forms may develop in 
consequence of the presence of vascular risk factors such as atherosclerosis or small vessel 
disease, and in post-stroke cases [Battistin et al., 2010, Thal et al., 2012]. 
Cognitive decline and dementia may present in several neurodegenerative disorders. 
Huntington’s disease (HD) is a chronic progressive disorder of autosomal dominant 
inheritance, which involves characteristic motor disturbances and a remarkable cognitive 
decline. The genetic background of HD is the polyglutamine expansion of the huntingtin gene 
[Tan et al., 2012] but recent genetic studies on yeasts have implicated several other genes 
which may influence the neurotoxic process, including kynurenine-3-monooxygenase (KMO) 
[Giorgini et al., 2005, Tauber et al., 2011]  
3. The kynurenine pathway and the role of kynurenines in dementia 
3.1. The kynurenine pathway 
The KP, the main route of the TRP metabolism, is responsible for the breakdown of more 
than 90% of the TRP in the human brain [Wolf, 1974]. This metabolic cascade involves 
several neuroactive metabolites, collectively termed kynurenines [Lapin, 1978, Zadori et al., 
2011]. Kynurenines have been shown to play important roles in the regulation of 
neurotransmission and in immunological processes [Vécsei, 2005, Zadori et al., 2011, Vecsei 
et al., 2013]. Alterations in the KP  have been implicated in the pathomechanism of cerebral 
ischaemia [Sas et al., 2008, Stone et al., 2012], migraine [Fejes et al., 2011, Tajti et al., 2011, 
Pardutz et al., 2012, Tajti et al., 2012], AIDS dementia complex (ADC) [Guillemin et al., 
2005] and several neurodegenerative disorders, including AD [Guillemin et al., 2002, Plangar 
et al., 2011, Zadori et al., 2011].  
The KP of the TRP catabolism comprises multiple enzymatic steps that result in the formation 
of the essential coenzymes nicotinamide adenine dinucleotide (NAD) and NAD phosphate 
[Beadle et al., 1947] (Fig. 1). The rate-limiting step of this metabolic route is the enzymatic 
degradation of TRP by indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase 
(TDO). The first stable intermediate in the KP is L-kynurenine (L-KYN), which can be 
converted in two different routes: either by the kynurenine aminotransferases (KATs) to form 
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the neuroprotective KYNA, or in a sequence of enzymatic steps which lead to the production 
of NAD [Beadle et al., 1947]. The four subtypes of KATs identified so far are mainly 
localized in the astrocytes within the brain [Okuno et al., 1991, Guillemin et al., 2001, Yu et 
al., 2006, Guidetti et al., 2007, Han et al., 2010]. In the human brain, KYNA production can 
be attributed mainly to the activity of KAT-II [Guidetti et al., 2007]. KYNA is a broad-
spectrum endogenous inhibitor of ionotropic excitatory amino acid receptors [Perkins et al., 
1982] and a non-competitive inhibitor of the α7 nicotinic acetylcholine receptor [Hilmas et 
al., 2001], and it was recently discovered that it may also be a ligand for the previously 
orphan G protein-coupled receptor GPR35 [Wang et al., 2006].  
In the other main branch of the KP, L-KYN serves as a substrate for kynurenine-3-
monooxygenase (KMO), resulting in the production of 3-hydroxy-kynurenine (3-HK) [Battie 
et al., 1981]. The continuing downstream metabolic cascade then produces the free radical 
generator 3-hydroxyanthranilic acid (3-HANA) and the NMDA receptor agonist quinolinic 
acid (QUIN) [Foster et al., 1986]. 3-HK and 3-HANA are potent free radical generators, 
while QUIN displays neurotoxic properties, not only through the production of free radicals, 
but also by NMDA-receptor agonism [Stone et al., 1981, De Carvalho et al., 1996].  
The enzymes participating in the KP are differently distributed among the different cells in 
the CNS: the microglial cells harbour little KAT, and the astrocytes contain hardly any KMO. 
KYNA production can therefore be attributed mainly to astrocytes, while microglial cells are 
primarily responsible for the synthesis of QUIN [Espey et al., 1997, Guillemin et al., 2001, 
Lehrmann et al., 2001].  
 
[Fig. 1. The kynurenine pathway] 
 
3.2. Kynurenine pathway alterations in Alzheimer’s disease 
An increasing body of evidence supports the notion that alterations in the KP are involved in 
the pathogenesis of AD [Baran et al., 1999, Widner et al., 2000]. As long ago as 1998, Baran 
demonstrated that the levels of 3-OH-KYN and L-KYN were slightly decreased in the brain 
of pathologically confirmed AD patients, while the level of KYNA exhibited a significant 
increase in the putamen and caudate nucleus. This elevation in KYNA correlated strongly 
with an increased KAT-I enzyme activity [Baran et al., 1999]. As concerns the peripheral 
kynurenine metabolism, the KYNA levels in the serum, red blood cells and CSF of AD 
patients were decreased, with no alterations in the serum KAT-I or KAT-II activity [Heyes et 
al., 1992, Hartai et al., 2007]. Moreover, an increased serum KYN/TRP ratio has been 
detected in AD patients, indicating an enhanced IDO activity, which may be explained by the 
role of inflammatory processes in the pathogenesis of AD [Widner et al., 2000]. Conversely, 
an increased IDO activity was correlated with several immune markers in the serum of AD 
patients [Widner et al., 2000]. Interestingly, an increased level of TRP degradation correlated 
with a reduced cognitive performance [Widner et al., 2000]. An increased QUIN and IDO 
6	  
	  
immunoreactivity has been detected in the hippocampus of AD patients [Guillemin et al., 
2005], pointing to the role of QUIN in the neurodegenerative process. This concept was 
further supported by the observation that QUIN is co-localized with hyperphosphorylated tau 
in the AD cortex, and QUIN also proved to induce tau phosphorylation in in vitro studies 
[Rahman et al., 2009].  
3.3. Kynurenine pathway in other conditions of cognitive decline 
The ADC is a characteristic dementia syndrome associated with human immunodeficiency 
virus type 1 infection. The neurotoxic kynurenine metabolite QUIN has been demonstrated to 
be involved in the development of the ADC. The significantly elevated levels of QUIN 
detected in the CSF of ADC patients correlated with the cognitive deficits, while zidovudine 
therapy resulted in a decreased QUIN level in parallel with a clinical improvement. These 
data raised the possibility that the neurotoxic properties of this metabolite contribute to 
disease progression [Heyes et al., 1991a, Heyes et al., 1991, Kaul et al., 2001]. Experimental 
data indicated that an elevated QUIN production reflected local macrophage activation in the 
CNS [Valle et al., 2004].  
KP metabolites have been associated with a post-surgical cognitive impairment and the 
alterations observed in this patient population additionally correlated with inflammatory 
markers [Forrest et al., 2011]. An enhanced kynurenine metabolism has been demonstrated to 
correlate with the infarct volume and mortality in stroke patients, and recent data suggested 
that an increased IDO activity resulting in a higher kynurenine/tryptophan ratio is associated 
with post-stroke cognitive impairment [Darlington et al., 2007, Gold et al., 2011]. Other 
studies have implicated kynurenine metabolites in vascular cognitive impairment and other 
neuropsychiatric conditions [Oxenkrug, 2007].  
Experimental data indicate a correlation between KP alterations and HD pathomechanism. In 
early stages of HD, increased levels of QUIN and 3-OH-KYN have been measured [Guidetti 
et al., 2004]. Beal et al. demonstrated in 1990 that KYNA levels are decreased in the striatum 
of HD patients [Beal et al., 1990]. Similarly, a reduced KAT activity has been demonstrated 
in several brain regions of HD patients [Jauch et al., 1995]. The results of a clinical study 
revealed an increased IDO and a decreased KAT activity, in parallel with an elevated level of 
oxidative stress [Stoy et al., 2005]. These alterations have been assumed to contribute to the 
disease development. Similar changes in KAT activity have been observed in an animal 
model of HD [Csillik et al., 2002]. Another animal study provided evidence of an increased 
vulnerability to the neurotoxicity of QUIN after KAT deletion, while elevation of the KYNA 
concentration proved to be protective [Harris et al., 1998, Sapko et al., 2006].  
3.4. Future therapeutic possibilities by targeting the kynurenine pathway 
The roles of the above-mentioned alterations in AD patients are still under investigation; the 
most feasible concept is that an accelerated kynurenine metabolism contributes to the 
neurodegenerative process through the overproduction of neurotoxic metabolites.  
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KYNA displays neuroprotective properties, but at concentrations above physiological it can 
exert adverse effects. The intracerebroventricular administration of KYNA resulted in 
behavioural abnormalities in rats, including stereotypy and ataxia [Vecsei et al., 1990], and in 
another study KYNA level elevations caused spatial working memory deficits [Chess et al., 
2007]. On the other hand, one animal study demonstrated that the inhibition of KYNA 
formation may be associated with an enhanced cognitive performance [Potter et al., 2010]. 
However, under the pathological conditions in neurodegenerative processes where 
glutamatergic excitotoxicity is present, inhibition of the overactivated glutamate receptors 
may restore the normal level of activation and improve the cognitive function. From this 
perspective, KYNA analogues may be a promising therapeutic tool in different pathologies 
relating to a cognitive impairment, by exerting a neuroprotective effect and restoring normal 
glutamatergic neurotransmission. 
KYNA itself can cross the blood-brain barrier only poorly [Fukui et al., 1991], and its 
systemic administration as a therapeutic tool is therefore not feasible. Furthermore, it is 
rapidly excreted from the brain by organic acid transporters [Bahn et al., 2005]. One 
therapeutic possibility would be the administration of L-KYN together with probenecid, an 
organic acid transporter inhibitor; this concept has been already tested under ischaemic 
conditions with good results [Gigler et al., 2007, Robotka et al., 2008]. Another possibility 
could be the administration of the halogenated L-KYN derivative 4-chlorokynurenine, which 
produces the KYNA analogue 6-chlorokynurenic acid. 4-chlorokynurenine has already 
successfully completed a Phase I clinical safety trial (for further information, see the press 
release on the VistaGen website) [Vecsei et al., 2013]. Other synthetic KYNA analogues have 
proved to be neuroprotective in different animal experiments including HD, and recent data 
provided evidence that this novel KYNA-amide does not exert cognitive side-effects 
[Knyihar-Csillik et al., 2008, Vamos et al., 2010, Zadori et al., 2011, Gellert et al., 2012]. 
Another approach could be the use of KMO inhibitors, which may shift the kynurenine 
metabolism towards KYNA production. KMO inhibition has been demonstrated to increase 
the brain KYNA concentration, improve spatial memory and anxiety deficits and prevent 
synaptic loss in a transgenic mouse model of AD [Zwilling et al., 2011]. The same compound 
tested in a HD animal model was able to slow down neurodegeneration and increase survival 
time [Zwilling et al., 2011]. Inhibition of KMO and TDO resulted in a shift of the KP towards 
KYNA formation and additionally ameliorated the neurodegenerative process in other animal 
models [Campesan et al., 2011]. 
4. Other possible novel therapeutic approaches in dementia 
The therapies currently available for AD have the aim of restoring the cholinergic and 
glutamatergic dysfunction; cholinesterase inhibitors and the glutamate-antagonist memantine 
are well-known and widely-used drugs. However, for other dementia types the 
recommendations are not so clear. The evidence supports the use of cholinesterase inhibitors 
and memantine in Lewy body disease and Parkinson’s disease dementia, with particular 
concern for side-effects; for other dementia types, there is currently no robust evidence in 
favour of any pharmacological approach [EFNS-ENS guideline-2012]. Intensive research is 
currently being carried out with a view to the development of novel therapeutic tools which 
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could possibly slow the disease progression besides providing symptomatic relief (Table 2) 
[Potter, 2010]. 
 
Table 2. Possible targets for drug development in Alzheimer’s disease [Potter, 2010] 
! cholinergic receptor agonists 
! vaccines against amyloid-ß 
! antibodies against amyloid-ß 
! secretase inhibitors 
! antiinflammatory drugs 
! tau-targeting agents 
 
Neuroinflammation is considered to be an important aspect in the pathomechanism of AD, 
and the observation from epidemiologic studies that nonsteroidal anti-inflammatory drugs 
(NSAIDs) were associated with a lower risk of AD gave rise to the concept of using anti-
inflammatory drugs for the treatment of dementia [Szekely et al., 2004]. In vitro studies 
yielded evidence that some NSAIDs were able to decrease the level of the amyloidβ-42 
peptide in cultured cells [Weggen et al., 2001], while ibuprofen treatment in an animal model 
of AD resulted in a reduction of the amyloid plaque load and microglial activation [Yan et al., 
2003]. Unfortunately, clinical trials have so far been disappointing [Aisen, 2002].  However, 
recently published data have suggested that selective COX-1 inhibitors may be of therapeutic 
value in AD, but further studies are needed to assess their efficacy [Choi et al., 2013]. 
The lipid metabolism was linked with AD when the apolipoprotein E (ApoE) allele 4 was 
identified as a major genetic risk factor for AD [Corder et al., 1993]. ApoE is a major 
cholesterol transport protein in the brain [Mahley, 1988]. The ApoE ε allele has been 
associated with an increased risk of cerebral amyloid angiopathy [Greenberg et al., 1995] and 
HIV disease progression [Burt et al., 2008], among others. ApoE, cholesterol and lipid 
metabolism alterations have been implicated in various stages of the pathogenesis of AD, 
including amyloid-ß protein production and clearance and cerebrovascular effects [Marzolo et 
al., 2009, Zlokovic, 2013]. Statins have been associated with a lower risk of AD in large 
epidemiological studies [Wolozin et al., 2000]. This can be explained in part by the fact that 
hyperlipidaemia is one of the major vascular risk factors and a cerebrovascular dysfunction 
may contribute to the development of AD. Moreover, statins have been reported to decrease 
amyloid-β peptide production  in a cholesterol-independent mechanism [Hosaka et al., 2013]. 
The amyloid-ß protein is produced from amyloid precursor protein in consequence of the 
proteolytic activity of β-secretase beta-site APP cleavage enzyme 1 (BACE1) and the γ-
secretase complex [Vassar, 2004]. Inhibition of BACE1 has been demonstrated to result in a 
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lower amyloid-ß protein level and to enhance cognitive impairment in an animal model of AD 
[Ohno et al., 2004]; BACE1 inhibitors may therefore be of therapeutic value in AD patients. 
The development of an orally available brain-penetrant BACE1 inhibitor was recently 
reported, which resulted in a reduced level of amyloid β protein formation in rats [Stamford et 
al., 2012], while another recently developed BACE1-inhibitor has already progressed to a 
Phase 1 clinical trial [Jeppsson et al., 2012]. 
 
5. Conclusions 
The pathomechanisms of different types of dementias are still under investigation, and the 
therapeutic possibilities are therefore limited. Neuroinflammatory processes, the lipid 
metabolism and secretase inhibitors are currently controversial fields as concerns drug 
development, but further research may facilitate an understanding. The alterations in the KP 
are common features in the neurodegenerative, cerebrovascular and immunological aspects of 
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